About 6,400 results

ALLMedicine™ Glioblastoma Multiforme Center

Research & Reviews  2,278 results

Glucose fluxes in glycolytic and oxidative pathways detected in vivo by deuterium magne...
NeuroImage. Clinical; Simões RV, Henriques RN et. al.

Jan 14th, 2022 - Glioblastoma multiforme (GBM), the most aggressive glial brain tumors, can metabolize glucose through glycolysis and mitochondrial oxidation pathways. While specific dependencies on those pathways are increasingly associated with treatment respons...

Dramatic clinical response in the treatment of small cell glioblastoma multiforme.
Journal of Clinical Pharmacy and Therapeutics; Zaman FY, McLean C et. al.

Jan 13th, 2022 - Small cell glioblastoma (scGBM) is a rare subtype of primary glioblastoma, which typically behave more aggressively compared with classical glioblastoma (GBMs). They are generally associated with poor responses to treatment, and optimal treatment ...

Functional virus-specific memory T cells survey glioblastoma.
https://doi.org/10.1007/s00262-021-03125-w 10.3389/fimmu.2021.676301 10.1038/s41571-018-0003-5 10.1038/s41467-019-08534-1 10.1016/j.immuni.2021.02.014 10.1038/s41467-018-05072-0 10.1158/0008-5472.CAN-11-2614 10.1038/s41586-018-0130-2 10.1038/ni.2568 10.1016/j.coviro.2016.11.011 10.1016/j.coi.2020.01.001 10.1126/science.1254536 10.1126/science.1254803 10.1016/j.smim.2020.101415 10.1007/s11060-017-2515-8 10.4049/jimmunol.169.4.1984 10.1126/sciimmunol.aas9673 10.1038/srep17187 10.1038/nature17655 10.4049/jimmunol.1201305 10.1038/s41586-021-03351-3 10.1084/jem.187.10.1575 10.1038/s41590-020-0711-8 10.1016/j.celrep.2019.08.038 10.1111/j.1349-7006.2006.00208.x 10.1038/nm.1863 10.1038/s41467-020-17704-5 10.1038/nature04606 10.1038/s41587-019-0404-8 10.3389/fimmu.2019.01962 10.1080/2162402X.2018.1514921 10.1158/1078-0432.CCR-20-1082 10.1172/JCI138649 10.1158/1078-0432.CCR-20-0176 10.1038/s41590-017-0029-3 10.1016/j.immuni.2021.06.013 10.1038/s41591-018-0135-2 10.1093/brain/awaa343 10.1016/j.nec.2020.12.003 10.1038/s41434-020-00207-9 10.1038/nprot.2014.005 10.1016/j.cell.2015.03.031 10.1038/nmeth.3317 10.1186/s13059-014-0550-8 10.1093/bioinformatics/btt703
Cancer Immunology, Immunotherapy : CII; Ning J, Gavil NV et. al.

Jan 11th, 2022 - Glioblastoma multiforme (GBM) is among the most aggressive, treatment-resistant cancers, and despite standard of care surgery, radiation and chemotherapy, is invariably fatal. GBM is marked by local and systemic immunosuppression, contributing to ...

A review of recent advances in magnetic nanoparticle-based theranostics of glioblastoma.
Nanomedicine (London, England); Dhar D, Ghosh S et. al.

Jan 11th, 2022 - Rapid vascular growth, infiltrative cells and high tumor heterogenicity are some glioblastoma multiforme (GBM) characteristics, making it the most lethal form of brain cancer. Low efficacy of the conventional treatment modalities leads to rampant ...

Sonobiopsy for minimally invasive, spatiotemporally-controlled, and sensitive detection...
Theranostics Pacia CP, Yuan J et. al.

Jan 7th, 2022 - Though surgical biopsies provide direct access to tissue for genomic characterization of brain cancer, they are invasive and pose significant clinical risks. Brain cancer management via blood-based liquid biopsies is a minimally invasive alternati...

see more →

Guidelines  1 results

The role of radiotherapy in the management of progressive glioblastoma : a systematic r...
Journal of Neuro-oncology; Ryu S, Buatti JM et. al.

Apr 15th, 2014 - Can re-irradiation (by using conventional radiotherapy, fractionated radiosurgery, or single fraction radiosurgery) be used in patients with progressive glioblastoma multiforme after the first adjuvant combined multimodality treatment with radiati...

see more →

Drugs  5 results see all →

Clinicaltrials.gov  154 results

Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme

Jan 6th, 2022 - The purpose of this study is to test the safety and effects of a combination of a study drug, Lapatinib, plus the administration of standard radiation therapy and an FDA approved drug Temozolomide (chemotherapy agent) in patients with newly diagno...

6 Months Adjuvant Temozolomide (TMZ) vs No Adjuvant TMZ in Newly Diagnosed MGMT Methylated Glioblastoma (GBM)

Jan 5th, 2022 - Recent phase III trials in patients with newly diagnosed patients with glioblastoma have demonstrated that adding new agents (such as cilengitide, bevacizumab, or nivolumab) to standard radiation and TMZ do not improve survival in this disease. Th...

Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide

Jan 3rd, 2022 - PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose Sarasar (SCH66336, lonafarnib) when combined with Temodar (temozolomide) in an alternating week schedule. II. To describe the toxicities of the Sarasar and Temodar combination treatmen...

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Dec 20th, 2021 - This first time-in patients (FTIP), open-label, multicentre study of AZD1390 will be conducted in the United States and in the United Kingdom, and it consists of three treatment arms: Arm A, B, C. This Phase 1 study will assess safety and tolerabi...

Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme

Dec 16th, 2021 - Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. The treatment comprises maximal safe resection followed by radiotherapy and chemotherapy. Despite appropriate management, 90% of the patients will develop relapse or p...

see more →

News  119 results

FDA Grants Fast Track Designation to ST101 for Recurrent Glioblastoma

Dec 6th, 2021 - The FDA has granted a fast track designation to ST101, a peptide antagonist of C/EBPβ, for the treatment of patients with recurrent glioblastoma, according to an announcement from Sapience Therapeutics, Inc., the drug developer.1 The decision is ...

Dr. Shi on the Rationale to Evaluate a Tumor-Treating Fields Therapy–Based Combination in Glioblastoma

Oct 25th, 2021 - Wenyin Shi, MD, PhD, professor, co-director, Brain Tumor Center, Sidney Kimmel Cancer Center, co-director, Stereotactic Radiosurgery Program, Jefferson University Hospitals, Jefferson Health, discusses the rationale to evaluate a tumor-treating fi...

Rini Discusses Variable Impact of Angiogenesis in Solid Tumors

Oct 6th, 2021 - Brian Rini, MD Brian I. Rini, MD, focuses on antiangiogenic therapy and immunotherapy for the treatment of renal cell carcinoma (RCC) and prostate cancer. He has been involved in the initial and ongoing development of targeted agents for metastat...

Developmental Interest in Allogeneic Placenta–Derived Cell Therapies Expands

Jul 16th, 2021 - Cellular medicine could represent the next frontier in the treatment of patients with cancer and many other diseases with a high unmet need. Although progress made with approaches like CAR T-cell therapies have served to advance the field forward,...

FDA Grants Fast Track Status to Berubicin for Recurrent Glioblastoma Multiforme

Jul 13th, 2021 - The FDA has granted a fast track designation to berubicin as a potential therapeutic option for patients with recurrent glioblastoma multiforme, according to an announcement issued by WPD Pharmaceuticals, Inc.1 Berubicin is an anthracycline, wh...

see more →

Patient Education  3 results see all →